Liver diseases therapeutics market| Coherent Market Insights

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. LIVER DISEASES THERAPEUTICS MARKET ANALYSIS Liver Diseases Therapeutics Market,TherapyType (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

3. The global liver diseases therapeutics market is estimated to account for US$ 12,851.3 Mn in terms of value in 2020 and is expected to reach US$ 24,921.3 Mn by the end of 2027. Drivers • Increasing prevalence of liver cancer is expected to propel growth of the global liver diseases therapeutics market over the forecast period.Forinstance,accordingto The American Cancer Society,in 2020,the U.S. is expected to record around 42,810 new cases and around 30,160 deaths due to primary liver cancer and intrahepatic bile duct cancer. • Moreover,increasinggeriatric population is also expected to aid in growth of the market.Forinstance,accordingto the U.S.CensusBureau,theU.S.geriatricpopulation is expected to reach 77 million by 2034.         • North America held dominant position in the global liver diseases therapeutics market in 2019,accounting for 38.6% share in terms of value,followedby Europe and Asia Pacific,respectively.

4. Figure 1.Global Liver Disease Therapeutics Market Share (%), by Region, 2019

5. MarketRestraints • Side effects and risks associated with liver diseases therapeutics is expected to hinder growth of the global liver diseases therapeutics market. The side effects associated with the use of liver therapeutics include, nausea, headache, fever loss of appetite, and drug-induced liver disease. • Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection is also expected to limit growth of the market.

6. Market Opportunities • R&D in immunotoxins is expected to offer lucrative growth opportunities for players in the global liver diseases therapeutics market. For instance, GPC3 is a cell surface heparansulfate proteoglycan that is overexpressed in hepatocellular carcinoma. Anti-GPC3 immunotoxins can be effective in the treatment of human hepatocellular carcinoma. • Moreover,clinicaltrials for development of new therapies is also expected to aid in growth of the market. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.’s PTG-300:

7. A subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis. • The global liver diseases therapeutics market was valued at US$ 11,854.7 Mn in 2019 and is forecast to reach a value of US$ 24,921.3 Mn by 2027 at a CAGR of 9.7% between 2020 and 2027.

8. Figure 2.Global Liver Disease Therapeutics Market Value (US$ Mn),and Y-o-Y Growth (%),2019-2027

9. Market Trends • Major organizations are focused on providing treatment guidelines for liver diseases during the COVID-19 pandemic. For instance, in March 2020, The American Association for the Study of Liver Disease released a clinical insight document for clinicians and frontline healthcare providers engaged in the treatment of patients with liver disease during the COVID-19 pandemic. • Increasing consumption of alcohol is expected to aid in growth of the market. For instance, according to the 2018 National Survey on Drug Use and Health (NSDUH), 86.3 percent of people ages 18 or older reported that they drank alcohol at some point in their lifetime.

10. Competitive Section Major players operating in the global liver diseases therapeutics market include, AstellasPharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxosmithklinePlc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

11. Key Development • Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for the development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. • Major players in the market are also focused on approval and launch of generic therapies for the treatment of liver diseases. For instance, in September 2019, Endo International received the U.S. FDA approval for its generic version of Syprine, a drug used for the treatment of Wilson's disease

12. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/liver-diseases-therapeutics-market-3809

13. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

14. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

15. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/